CerFlux
CerFlux is a personalized medicine company focused on 'Crushing Cancer' by precisely matching treatments to individual patient tumors. Their patented POET® (Personalized Oncology Efficacy Test) platform screens multiple therapy agents simultaneously on a patient's biopsy tissue, providing results in under 7 days. This approach aims to overcome the limitations of current generalized treatment methods, which are often inaccurate and lead to ineffective overtreatment, causing significant pain, cost, and lost time for patients. By identifying the right treatment for each patient before therapy begins, CerFlux seeks to improve outcomes, reduce the burden of ineffective treatments, and accelerate the drug development process.
CerFlux
CerFlux is a personalized medicine company focused on 'Crushing Cancer' by precisely matching treatments to individual patient tumors. Their patented POET® (Personalized Oncology Efficacy Test) platform screens multiple therapy agents simultaneously on a patient's biopsy tissue, providing results in under 7 days. This approach aims to overcome the limitations of current generalized treatment methods, which are often inaccurate and lead to ineffective overtreatment, causing significant pain, cost, and lost time for patients. By identifying the right treatment for each patient before therapy begins, CerFlux seeks to improve outcomes, reduce the burden of ineffective treatments, and accelerate the drug development process.